VINCENZI, Fabrizio
 Distribuzione geografica
Continente #
NA - Nord America 9.914
EU - Europa 3.104
AS - Asia 2.263
SA - Sud America 229
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 4
Totale 15.540
Nazione #
US - Stati Uniti d'America 9.857
CN - Cina 1.023
IT - Italia 882
SG - Singapore 655
UA - Ucraina 506
DE - Germania 467
TR - Turchia 384
PL - Polonia 337
GB - Regno Unito 284
BR - Brasile 207
FI - Finlandia 193
SE - Svezia 166
ID - Indonesia 101
FR - Francia 55
CA - Canada 50
BE - Belgio 46
RU - Federazione Russa 36
NL - Olanda 30
CZ - Repubblica Ceca 26
HK - Hong Kong 23
VN - Vietnam 23
AT - Austria 17
CH - Svizzera 16
LT - Lituania 15
EU - Europa 8
IE - Irlanda 7
JP - Giappone 7
CL - Cile 6
IN - India 6
BD - Bangladesh 5
IQ - Iraq 5
AU - Australia 4
CO - Colombia 4
HU - Ungheria 4
IR - Iran 4
KR - Corea 4
PK - Pakistan 4
RO - Romania 4
UZ - Uzbekistan 4
AR - Argentina 3
MA - Marocco 3
PT - Portogallo 3
PY - Paraguay 3
TN - Tunisia 3
VE - Venezuela 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
CI - Costa d'Avorio 2
GE - Georgia 2
IL - Israele 2
NO - Norvegia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BG - Bulgaria 1
CG - Congo 1
CR - Costa Rica 1
DZ - Algeria 1
EC - Ecuador 1
ES - Italia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MX - Messico 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SC - Seychelles 1
TH - Thailandia 1
TW - Taiwan 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 15.540
Città #
Fairfield 1.187
Woodbridge 1.155
Chandler 795
Ann Arbor 709
Houston 706
Ashburn 643
Jacksonville 615
Santa Clara 571
Singapore 496
Seattle 488
Wilmington 469
Cambridge 421
Ferrara 348
Warsaw 336
Izmir 234
Beijing 232
Nanjing 168
Princeton 163
Shanghai 131
Milan 113
Boardman 111
San Diego 105
Jakarta 100
Los Angeles 78
Helsinki 73
New York 59
Bremen 57
Nanchang 52
Shenyang 49
Dearborn 47
Tianjin 45
Brussels 44
London 42
Bologna 37
Hebei 36
Jiaxing 35
Falls Church 34
Toronto 32
Changsha 28
Munich 28
Frankfurt am Main 26
Auburn Hills 24
Brno 23
Norwalk 23
Zhengzhou 23
Dong Ket 22
Hong Kong 22
Falkenstein 21
Mountain View 21
Washington 20
Council Bluffs 18
Nuremberg 18
Guangzhou 17
Kunming 17
São Paulo 17
Des Moines 16
Jinan 16
Orange 16
Zurich 15
Addison 14
Ferrara di Monte Baldo 14
Ottawa 14
Redwood City 14
San Mateo 13
Ningbo 12
Tappahannock 12
Augusta 10
Venice 10
Verona 9
Indiana 8
Nice 8
Rome 8
Chicago 7
Curitiba 7
Espoo 7
Ipswich 7
Kilburn 7
Vienna 7
Belo Horizonte 6
Florence 6
Hangzhou 6
Istanbul 6
Modena 6
Montebelluna 6
Rio de Janeiro 6
San Francisco 6
Tokyo 6
Aversa 5
Brasília 5
Dublin 5
Haikou 5
Hefei 5
Las Vegas 5
Philadelphia 5
San Antonio 5
Taizhou 5
Bari 4
Cagliari 4
Castelnuovo di Porto 4
Chiswick 4
Totale 11.750
Nome #
Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies 255
Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455 203
Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice 189
ALTERED EXPRESSION AND FUNCTIONALITY OF A2A ADENOSINE RECEPTORS IN HUNTINGTON’S DISEASE AND OTHER POLYGLUTAMINE DISORDERS 177
Pharmacology of Adenosine Receptors: The State of the Art 177
Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice 175
The A3 adenosine receptor: history and perspectives 168
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 165
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 161
Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts 155
Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety 155
Psychostimulant effect of the synthetic cannabinoid JWH-018 and AKB48. Behavioural, neurochemical and Dopamine transporter scan imaging studies in mice 153
The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles 150
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 148
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells 146
Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors 146
Pathological overproduction: the bad side of adenosine 146
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 142
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease 139
Multiple sclerosis lymphocytes upregulate A(2A) adenosine receptors that are antiinflammatory when stimulated 139
Role and function of A2A and A3 adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis 138
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A2A Adenosine Receptor Inverse Agonists with Antinociceptive Activity 138
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 137
A(2B) adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway 137
A(2A) adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients 137
Repeated dosing with NCX1404, a nitric oxide-donating pregabalin, re-establishes normal nociceptive responses in mice with streptozotocin-induced painful diabetic neuropathy 133
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 132
A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release 130
Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[(4- arylpiperazin-1-yl)methyl]-5-substituted-thiophenes. Effect of the 5-modification on allosteric enhancer activity at the A1 adenosine receptor 130
Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. 130
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 129
Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields. 126
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 126
P2X1 and P2X3 Purinergic Receptors Differentially Modulate the Inflammatory Response in Human Osteoarthritic Synovial Fibroblasts 125
ALTERATION OF ADENOSINE RECEPTORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 125
F638 a nitric oxide (NO)-donating gabapentin, NCX 1236, reverses the development of mechanical allodynia in streptozotocin-treated diabetic mice. 125
Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N- (substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor 125
Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts 124
Binding thermodynamic characterization of human P2X1 and P2X3 purinergic receptors 123
null 121
Functional tissue engineering in articular cartilage repair: is there a role for electromagnetic biophysical stimulation? 120
The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells 119
Synthesis and Biological Evaluation of Novel Allosteric Enhancers of the A1 Adenosine Receptor Based on 2-Amino-3-(4’-Chlorobenzoyl)-4-Substituted-5-Arylethynyl Thiophene 119
Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies 119
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 116
Thermodynamic analysis in drug-receptor binding: the A3 adenosine receptor 115
The role of adenosine receptors in rheumatoid arthritis. 114
Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 114
Biochemical and pharmacological role of A1adenosine receptors and their modulation as novel therapeutic strategy 114
Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes 112
Cannabigerol action at cannabinoid CB1 and CB2 receptors and at CB1-CB2 heteroreceptor complexes 112
Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields 112
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 111
Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: From triazoloquinoxaline to a pyrimidine skeleton as a key study 109
Structure-activity relationships of 2-amino-3-aroyl-4-[(4-arylpiperazin-1- yl)methyl]thiophenes. Part 2: Probing the influence of diverse substituents at the phenyl of the arylpiperazine moiety on allosteric enhancer activity at the A 1 adenosine receptor 108
null 107
Effect of pulsed electromagnetic field exposure on adenosine receptors in rat brain 107
Alteration of adenosine receptore in patients with chronic obstructive pulmonary disease 107
A3 Receptors are Overexpressed in Pleura from Mesothelioma Patients and Reduce Cell Growth via Akt/NF-kB Pathway. 106
null 106
[3H]MRE2029F20 a new selective antagonist radioligand for the human A2B adenosine receptors. 104
null 104
A3 adenosine receptors are overexpressed in pleura from patients with mesothelioma and reduce malignant mesothelioma cell growth 101
Targeting A3 and A2A adenosine receptors in the fight against cancer 100
Effect of low frequency electromagnetic fields on A2A and A3 adenosine receptors in human neutrophils 99
Pharmacological characterization of adenosine receptors in bovine chondrocytes. 99
Pulsed electromagnetic field and relief of hypoxia-induced neuronal cell death: The signaling pathway 99
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 96
Development of novel pyridazinone-based adenosine receptor ligands 96
Effects of pulsed electromagnetic field exposure and adenosine analogues on prostaglandin release in bovine synovial fibroblasts. 95
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats 95
Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in human renal cells: Implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells. 95
null 94
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 94
RAW 264.7 co-cultured with ultra-high molecular weight polyethylene particles spontaneously differentiate into osteoclasts: an in vitro model of periprosthetic osteolysis 94
null 93
Anxiolytic properties of A1 adenosine receptor PAMs 93
Pharmacological characterization of P2X1 and P2X3 purinergic receptors in bovine chondrocytes 92
null 92
Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A3 adenosine receptors in human renal cells 92
null 91
null 91
null 88
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 88
null 86
Signaling pathways involved in anti-inflammatory effects of Pulsed Electromagnetic Field in microglial cells 86
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 86
Effects of pulsed electromagnetic fields and platelet rich plasma in preventing osteoclastogenesis in an in vitro model of osteolysis 86
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 85
Effect of Pulsed Electromagnetic Field Exposure on Adenosine Receptors in Human Fibroblast-like Synoviocytes 84
null 84
null 83
null 83
null 83
NCX 1236, a novel gabapentin endowed of nitric oxide-releasing properties, reverses the development of mechanical allodynia in streptozotocin-treated diabetic mice 82
Effect of chronic caffeine intake on A2A adenosine receptors in human neutrophils. 82
Adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes 81
null 81
null 81
null 79
Totale 11.744
Categoria #
all - tutte 83.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.483
Totale 84.941


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.025 0 0 0 0 0 0 0 288 234 295 152 56
2020/20212.582 147 157 105 260 194 254 186 321 111 423 289 135
2021/20221.497 46 155 119 34 50 82 101 97 63 128 237 385
2022/20231.779 176 190 47 259 260 220 122 143 192 18 85 67
2023/20241.078 88 111 51 33 106 137 66 116 19 41 38 272
2024/20252.380 109 151 374 288 469 510 241 238 0 0 0 0
Totale 15.925